期刊
DRUGS OF TODAY
卷 48, 期 6, 页码 395-403出版社
PROUS SCIENCE, SAU-THOMSON REUTERS
DOI: 10.1358/dot.2012.48.6.1825620
关键词
Chronic kidney disease; Anemia; Erythropoietin; Erythropoiesis-stimulating agents; Peginesatide
Anemia is a major complication in patients with chronic kidney disease, as the damaged kidney is unable to produce enough erythropoietin. Peginesatide (formerly known as Hematide (TM)) is a synthetic, peptide-based erythropoiesis-stimulating agent linked to polyethylene glycol. Based on extensive preclinical and clinical data substantiating the efficacy and safety of this agent, it was approved in the U.S. in March 2012 for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. Peginesatide (Omontys (R)) was launched in the U.S. in April 2012.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据